API | nuc-3373

nuc-3373 Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Chemistry

SMILES: C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)C[C@@H]1O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1
InChIKey: BIOWRMNRHMERIO-ZVAHOJSLSA-N
Mol. Mass: 613.54
ALogP: 3.4 Partition coefficient
ChEMBL Molecule:
fosifloxuridine nafalbenamide

More Chemistry

Pharmacology

Mechanism of Action:
- Thymidylate synthase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

nuc-3373

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Hodgkin Disease (Phase 1/Phase 2)

Melanoma (Phase 1/Phase 2)

Mesothelioma (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue